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the actin cytoskeleton in podocytes. 13 Th e 
same may be true for high-dose DEXA. 14 
 Currently, the treatment of FSGS can be 
considered as a voyage between Scylla and 
Charybdis. On one hand, we need to use 
prolonged aggressive therapy in patients 
with idiopathic FSGS who may respond, 
although response may take at least 4 
months of therapy. On the other hand, many 
patients with FSGS do not have idiopathic 
FSGS and will not respond to conventional 
immunosuppressive therapy, and such expo-
sure will put these patients at risk. Th e debate 
on the best treatment options for FSGS will 
continue. Since FSGS is not one disease, it is 
not surprising that the literature data on 
FSGS are so heterogeneous, results being 
dependent on the composition of the study 
population. Th e FSGS trial clearly illustrates 
that randomized controlled trials are diffi  -
cult to perform. Before embarking on new 
intervention studies, we need to develop bet-
ter clinical definitions for patients with 
FSGS, based on strict diagnostic and prog-
nostic criteria. Prospective registry data 
could provide these criteria. In addition, 
studies must be directed at identifying risk 
markers for progression and outcome. 
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 SUPPLEMENTARY MATERIAL 
 Table S1. Remission rate in studies in patients 
with steroid resistant FSGS using prolonged 
and / or high dose corticosteroid therapy. 
 Table S2. Remission rate in studies in 
patients with steroid resistant FSGS using 
calcineurin inhibitors with / without high dose 
corticosteroids.
Supplementary material is linked to the 
online version of the paper at  http://www.
nature.com/ki  
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 Transplant glomerulopathy: it ’ s 
not always about chronic rejection 
 Mark  Haas 1 
 Transplant glomerulopathy (TG) is a morphologic lesion of renal 
allografts characterized by duplication of the glomerular basement 
membrane and is widely accepted as a manifestation of chronic 
antibody-mediated rejection (AMR). However, TG is not specific for 
chronic AMR, and this pattern of injury may result from a number of 
disease processes affecting the glomerular endothelium. Baid-Agrawal 
and co-workers consider three different, but not mutually exclusive, 
processes that can produce morphologic lesions of TG: chronic AMR, 
hepatitis C, and thrombotic microangiopathy. 
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 Transplant glomerulopathy (TG) is a mor-
phologic lesion of renal allografts that is 
characterized histologically by duplication 
and / or multilayering of the glomerular base-
ment membrane. It is best appreciated on 
tissue sections stained with silver stains that 
highlight the glomerular basement mem-
brane ( Figure 1 ) and is only infrequently 
seen before 1 year post-transplantation, 1,2 
although earlier lesions may be appreciated 
by electron microscopy. 3 TG, and the closely 
related lesion of peritubular capillary (PTC) 
basement membrane multilayering, are felt 
to represent manifestations of chronic rejec-
tion, particularly chronic antibody-mediated 
rejection (AMR). 4 TG is well documented 
to be associated with the presence of anti-
bodies against the renal allograft , most nota-
bly antibodies against human leukocyte 
antigen class II antigens, and the presence of 
histologic lesions of TG on a renal allograft  
biopsy is a predictor of reduced long-term 
graft  survival. 2,5 
 Sis and co-workers 6 included TG, 
together with PTC basement membrane 
multilayering, PTC C4d deposition, and 
donor-specific antibodies (DSAs), in 
their  ‘ABCD tetrad ’ indicative of chronic-
active AMR in renal allograft s. However, 
only 73 % of their cases of TG were associated 
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with DSA or C4d, leaving more than one-
fourth of cases of TG outside of this tetrad. 
Several studies (for example, Cosio  et al. 2,7 ) 
had suggested an association between hepa-
titis C virus (HCV) and TG in renal allo-
graft s; however, in these studies most or all 
biopsies were examined by light micro scopy 
only. HCV is associated with, and is felt to be 
a causative agent of, recurrent and  de novo 
membranoproliferative glome rulonephritis 
(MPGN) in renal allograft s, 8 and by light 
microscopy alone TG can closely resemble 
MPGN, particularly if the former is accom-
panied by active transplant glomerulitis ( Fig-
ure 1 ). Another potential cause of TG 
unrelated to alloantibody could be throm-
botic microangiopathy (TMA), which has 
multiple potential etiologies, including cal-
cineurin inhibitor (CNI) nephrotoxicity. 9 
TMA is manifest by injury to endothelial 
cells and, in a chronic or smoldering form, 
can produce a pattern of glomerular injury 
with prominent GBM duplication. 
 Baid-Agrawal and co-workers 10 (this 
issue) examine these three potential causes 
of TG in a series of 25 renal allograft  biop-
sies, performed for evaluation of chronic 
renal allograft  dysfunction and / or proteinu-
ria. In all 25 biopsies, MPGN was ruled out, 
as no immune complex deposits were seen 
by immunofluorescence and / or electron 
microscopy. In at least 21 of these, possibly 
as many as 24 (including three cases with 
chronic CNI toxicity without diagnostic 
changes of TMA), the changes of TG could 
be accounted for by alloantibody (C4d dep-
osition in PTC, with  de novo DSA in seven 
of eight cases with available serum), HCV, 
and / or TMA. Fift een biopsies with diagnos-
tic changes had only one cause of TG (nine 
alloantibody, three HCV, three TMA), while 
six others had HCV and C4d or HCV and 
TMA. TMA and HCV were often seen 
together; the majority of biopsies from HCV-
positive patients had fi ndings of TMA, and 
vice versa. 10 A particularly notable fi nding 
was that graft  survival from the time of trans-
plantation, as determined by time-to-event 
(Kaplan – Meier) analysis, was signifi cantly 
shorter in HCV-positive patients with TG 
than in HCV-negative patients with TG. 10 
 A potential shortcoming of this study 10 
is the use of C4d staining to defi ne cases of 
TG caused by alloantibody, with DSA data 
at the time of biopsy available in only 12 of 
25 cases. Sis and co-workers 11 have defi ned 
a subgroup of renal allograft biopsies 
showing antibody-induced graft  injury in 
the absence of C4d, defi ned by expression 
of endothelial transcripts and the presence 
of DSA. Furthermore, Loupy  et al. 12 found 
that TG may develop in the presence of 
DSA in graft s showing glomerulitis and / or 
peritubular capillaritis, without C4d. Still, 
in the study of Baid-Agrawal  et al. , 10 two 
HCV-positive patients with TG and nega-
tive C4d also had negative DSA, suggesting 
that in at least some cases HCV can pro-
duce TG in the absence of alloantibody. 
 How might HCV infection produce 
morphologic lesions of TG in these latter 
cases? One possibility might involve low 
levels of immune complex deposits and / or 
cryoglobulins producing MPGN-type 
lesions, with resorption of these glomerular 
deposits prior to biopsy. Alternatively, and 
perhaps more likely, noting the frequent 
overlap of HCV and TMA in the lesions of 
TG studied by Baid-Agrawal  et al. , 10 HCV 
may produce a lesion of TMA involving the 
glomeruli. In an earlier study of 18 renal 
allograft  recipients who were HCV-positive 
at the time of transplantation, Baid  et al. 13 
found that fi ve patients developed TMA 
between 5 and 120 days post-transplanta-
tion, and that all fi ve had anti-cardiolipin 
antibodies. By contrast, only one of 13 
HCV-positive patients without TMA and 
none of seven HCV-negative patients 
with recurrent or  de novo TMA had anti-
cardiolipin antibodies. 13 
 As is noted above, the presence of TG on 
a renal allograft  biopsy is associated with 
poor graft  survival, 2,5 and the data of Baid-
Agrawal  et al. 10 indicate that graft  survival 
with TG is even worse in HCV-positive 
patients. However, regardless of the etiol-
ogy, there is no significant evidence at 
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 Figure 1  |  Histologic lesions of transplant glomerulopathy in renal allograft biopsies. 
( a ) Multiple double contours of the glomerular basement membrane (GBM) are apparent on 
the silver methenamine stain. Segmental glomerulosclerosis is also present, with associated 
protein insudates that appear pink on this stain. There is minimal glomerulitis present, and this 
lesion of transplant glomerulopathy (TG) is easily differentiated from membranoproliferative 
glomerulonephritis (MPGN). ( b ) In addition to TG with GBM double contours, this glomerulus 
also shows severe, active glomerulitis with numerous intracapillary leukocytes and mild lobular 
accentuation. As such, this lesion cannot be definitely distinguished from MPGN, although the 
latter was ruled out by the absence of immune complex deposits by immunofluorescence and 
electron microscopy. ( a and  b , silver methenamine stain; original magnification,  × 400). 
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present that histologic lesions of TG are 
reversible with therapy, whether this be 
removal of DSA, treatment of HCV, lower-
ing of CNI dose, or other treatment, and 
once TG is apparent by light microscopy, 
the fate of the graft  may already be sealed. 
 Indeed, an important key to prolonging 
graft  survival would appear to be preven-
tion of TG, and in this regard, recognizing 
those graft s at high risk for developing TG 
is an important step toward this goal. Our 
fi ndings in patients with DSA, glomerulitis, 
and / or peritubular capillaritis, and early 
ultrastructural findings that have been 
reported in graft s that later develop TG, 3 
suggest that early treatment with intrave-
nous immunoglobulin, plasmapheresis, 
and / or rituximab may prevent or at least 
delay the onset of TG. 14 By expanding the 
list of potential etiologies of TG, Baid-
Agrawal and co-workers 10 have opened the 
door for studies of early treatment of other 
potential causes of TG, particularly HCV. 
It will also be important to determine 
whether there are specifi c subsets of HCV-
positive allograft recipients who are at 
greatest risk for developing TG, just as 
DSAs against human leukocyte antigen 
class II antigens are most closely associated 
with TG. 2,5 For example, does HCV-associ-
ated TG occur signifi cantly more oft en, 
or earlier post-transplantation, when there 
is also evidence of TMA? If so, might 
the presence of anti-cardiolipin antibodies 
represent an important risk factor for 
development of TG in these patients? Are 
HCV-positive graft  recipients treated with 
CNI-sparing immunosuppressive regimens 
less likely to develop TG than patients 
receiving standard doses of CNIs? 
 In summary, it is important for us to 
recog nize that TG is not a specifi c diagno-
sis that can be equated with chronic or 
chronic-active AMR but is rather a pattern 
of graft injury with a number of non-
mutually-exclusive etiologies that now 
include HCV and TMA in addition to 
AMR. More importantly, we can now focus 
even more on determining which patients 
among those with alloantibody, HCV, 
and / or TMA are at greatest risk for devel-
oping TG and why, and what can be done 
therapeutically to reduce this risk. 
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 Olfactory function in dialysis 
patients: a potential key to 
understanding the uremic state 
 Andrew S.  Bomback 1 and  Amanda C.  Raff 2 
 Impaired olfactory function is a marker of neurologic dysfunction in 
the uremic state. Retained uremic toxins not adequately cleared with 
dialysis may undermine the integrity of the olfactory epithelium and 
olfactory bulb and malign central olfactory processing. The evidence 
suggests that only renal transplantation, with its concomitant thorough 
reversal of uremia, truly restores olfactory function to normal in end-
stage renal disease. Testing of olfactory function may emerge as an 
important marker for the extent and resolution of uremia. 
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 Th e excessive morbidity and mortality 
that affl  icts the end-stage renal disease 
(ESRD) population on maintenance dial-
ysis has received signifi cant attention in 
both the medical and the mass-market 
literature. While these depressing statistics 
should by no means be ignored, what 
oft en strikes dialysis providers rounding 
in outpatient units is the poor day-to-day 
